News

BioSpace
biospace.com > drug-development > after-the-jpm-hype-a-reality-check-why-your-2026-strategy-hinges-on-your-manufacturing-toolkit

After the JPM Hype, a Reality Check: Why your 2026 Strategy Hinges on your Manufacturing Toolkit

After the JPM Hype, a Reality Check: Why your 2026 Strategy Hinges on your Manufacturing Toolkit2+ hour, 23+ min ago   (282+ words) The banners are down, the last of the San Francisco fog has lifted, and the biotech world is collectively nursing its post-J.P. Morgan Healthcare Conference hangover. The promises of 2026 are grand: AI-driven discovery will revolutionize R&D. Multi-specifics will conquer "undruggable…...